Novel Applications of COX-2 Inhibitors, Metformin, and Statins for the Primary Chemoprevention of Breast Cancer

Overview

Journal J Turk Ger Gynecol Assoc

Publisher Galenos Publishing House

Specialty Gynecology & Obstetrics

Date 2016 Dec 20

PMID 27990091

Citations 6

Authors

Darren Micallef

Sarah Micallef

Pierre Schembri-Wismayer

Jean Calleja-Agius

Affiliations

Soon will be listed here.

Abstract

Recent evidence shows that commonly prescribed drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs), metformin, and statins, may have beneficial roles in the primary chemoprevention of breast cancer. Therefore, these drugs could potentially be used in addition to the hormonal drugs currently used for this purpose (namely, selective estrogen receptor modulators and aromatase inhibitors) due to their alternative mechanisms of action.

Citing Articles

Natural Products for the Prevention, Treatment and Progression of Breast Cancer.

Svolacchia F, Brongo S, Catalano A, Ceccarini A, Svolacchia L, Santarsiere A Cancers (Basel). 2023; 15(11).

PMID: 37296944 PMC: 10252020. DOI: 10.3390/cancers15112981.

Metformin in the management of fibrocystic breast disease: a placebo-controlled randomized clinical trial.

Alipour S, Rastad H, Saberi A, Faiz F, Maleki-Hajiagha A, Abedi M Daru. 2021; 29(2):389-396.

PMID: 34719004 PMC: 8557102. DOI: 10.1007/s40199-021-00424-6.

Preclinical meritorious anticancer effects of Metformin against breast cancer: An trial.

Rizvi F, Shaukat L, Azhar A, Jafri A, Aslam U, Imran-Ul-Haq H J Taibah Univ Med Sci. 2021; 16(4):504-512.

PMID: 34408607 PMC: 8348326. DOI: 10.1016/j.jtumed.2021.02.006.

The Dualistic Effect of COX-2-Mediated Signaling in Obesity and Insulin Resistance.

Chan P, Liao M, Hsieh P Int J Mol Sci. 2019; 20(13).

PMID: 31247902 PMC: 6651192. DOI: 10.3390/ijms20133115.

Metformin and Breast Cancer: Molecular Targets.

Faria J, Negalha G, Azevedo A, Martel F J Mammary Gland Biol Neoplasia. 2019; 24(2):111-123.

PMID: 30903363 DOI: 10.1007/s10911-019-09429-z.

References

Nyholm H, Djursing H, Hagen C, Agner T, Bennett P, Svenstrup B . Androgens and estrogens in postmenopausal insulin-treated diabetic women. J Clin Endocrinol Metab. 1989; 69(5):946-9. DOI: 10.1210/jcem-69-5-946. View

Hermann L . Metformin: a review of its pharmacological properties and therapeutic use. Diabete Metab. 1979; 5(3):233-45. View

Jiralerspong S, Palla S, Giordano S, Meric-Bernstam F, Liedtke C, Barnett C . Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009; 27(20):3297-302. PMC: 2736070. DOI: 10.1200/JCO.2009.19.6410. View

Santa-Maria C, Stearns V . Statins and Breast Cancer: Future Directions in Chemoprevention. Curr Breast Cancer Rep. 2013; 5(3):161-169. PMC: 3752917. DOI: 10.1007/s12609-013-0119-7. View

Katz M . Therapy insight: Potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol. 2005; 2(2):82-9. DOI: 10.1038/ncponc0097. View

Hirose K, Toyama T, Iwata H, Takezaki T, Hamajima N, Tajima K . Insulin, insulin-like growth factor-I and breast cancer risk in Japanese women. Asian Pac J Cancer Prev. 2003; 4(3):239-46. View

Cauley J, Zmuda J, Lui L, Hillier T, Ness R, Stone K . Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt). 2003; 12(8):749-56. DOI: 10.1089/154099903322447710. View

Key T, Appleby P, Barnes I, Reeves G . Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002; 94(8):606-16. DOI: 10.1093/jnci/94.8.606. View

Funk C, FitzGerald G . COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol. 2007; 50(5):470-9. DOI: 10.1097/FJC.0b013e318157f72d. View

10.

Blais L, Desgagne A, LeLorier J . 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med. 2000; 160(15):2363-8. DOI: 10.1001/archinte.160.15.2363. View

11.

Renehan A, Harvie M, Howell A . Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer. 2006; 13(2):273-8. DOI: 10.1677/erc.1.01219. View

12.

Stancu C, Sima A . Statins: mechanism of action and effects. J Cell Mol Med. 2002; 5(4):378-87. PMC: 6740083. DOI: 10.1111/j.1582-4934.2001.tb00172.x. View

13.

Uray I, Brown P . Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. Recent Results Cancer Res. 2011; 188:147-62. PMC: 3415693. DOI: 10.1007/978-3-642-10858-7_13. View

14.

Verheus M, Peeters P, Rinaldi S, Dossus L, Biessy C, Olsen A . Serum C-peptide levels and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2006; 119(3):659-67. DOI: 10.1002/ijc.21861. View

15.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

16.

Mason R, Walter M, Jacob R . Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation. 2004; 109(21 Suppl 1):II34-41. DOI: 10.1161/01.CIR.0000129503.62747.03. View

17.

Ch Yiannakopoulou E . Aspirin and NSAIDs for breast cancer chemoprevention. Eur J Cancer Prev. 2014; 24(5):416-21. DOI: 10.1097/CEJ.0000000000000098. View

18.

Del Barco S, Vazquez-Martin A, Cufi S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J . Metformin: multi-faceted protection against cancer. Oncotarget. 2011; 2(12):896-917. PMC: 3282095. DOI: 10.18632/oncotarget.387. View

19.

Laufs U, Liao J . Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med. 2001; 10(4):143-8. DOI: 10.1016/s1050-1738(00)00044-x. View

20.

Liao S, Li J, Wei W, Wang L, Zhang Y, Li J . Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pac J Cancer Prev. 2011; 12(4):1061-5. View